Hongmei Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hongmei Ye has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jing Guo
Peking University People's Hospital
1 shared publication Lin Huang
Peking University People's Hospital
1 shared publicationSiyu Meng
Peking University People's Hospital
1 shared publicationXiaohong Zhang
Peking University People's Hospital
1 shared publication- Xinyu Wang
Peking University People's Hospital
1 shared publication Xu He
Peking University People's Hospital
1 shared publication
Latest Publications
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e046773
HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation
Background: Several studies have suggested that N6‐methyladenosine (m6A) plays an essential role in cardiovascular disease, but the causality of m6A on ischemic heart disease (IHD) remains unknown. Therefore, this study investigated the potential relationship between m6A and IHD using a 2‐sample Mendelian randomization method. Methods: The publicly available genome‐wide association study data for m6A‐related proteins were obtained from the INTERVAL study, a large population‐based cohort of healthy blood donors in the United Kingdom, whereas the genome‐wide association study database (including 30 952 cases and 187 840 healthy controls) provided the IHD data. We performed a 2‐sample Mendelian randomization analysis to evaluate the potential causal association between HNRNPC (heterogeneous nuclear ribonucleoprotein C) and IHD, followed by experimental validation in vitro and in vivo to confirm the role of HNRNPC in IHD pathogenesis. Results: There was no indication of pleiotropy or heterogeneity among the 6 m6A‐associated proteins, but Mendelian randomization analysis revealed that HNRNPC (odds ratio [OR], 0.93 [95% CI, 0.88–0.97]; P =0.002) was associated with IHD. When IHD developed, there was a significant upregulation of HNRNPC expression in both animal and cellular tests. HNRNPC knockdown prevented oxidative stress, mitochondrial dysfunction, and cell death. Conclusions: The Mendelian randomization study suggests a potential causal association of the m6A‐related protein HNRNPC in the cause of IHD and verified the accuracy of the results through a series of experiments, which will help us understand the pathogenesis of IHD and identify potential therapeutic targets in the future.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e046773
HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation
Background: Several studies have suggested that N6‐methyladenosine (m6A) plays an essential role in cardiovascular disease, but the causality of m6A on ischemic heart disease (IHD) remains unknown. Therefore, this study investigated the potential relationship between m6A and IHD using a 2‐sample Mendelian randomization method. Methods: The publicly available genome‐wide association study data for m6A‐related proteins were obtained from the INTERVAL study, a large population‐based cohort of healthy blood donors in the United Kingdom, whereas the genome‐wide association study database (including 30 952 cases and 187 840 healthy controls) provided the IHD data. We performed a 2‐sample Mendelian randomization analysis to evaluate the potential causal association between HNRNPC (heterogeneous nuclear ribonucleoprotein C) and IHD, followed by experimental validation in vitro and in vivo to confirm the role of HNRNPC in IHD pathogenesis. Results: There was no indication of pleiotropy or heterogeneity among the 6 m6A‐associated proteins, but Mendelian randomization analysis revealed that HNRNPC (odds ratio [OR], 0.93 [95% CI, 0.88–0.97]; P =0.002) was associated with IHD. When IHD developed, there was a significant upregulation of HNRNPC expression in both animal and cellular tests. HNRNPC knockdown prevented oxidative stress, mitochondrial dysfunction, and cell death. Conclusions: The Mendelian randomization study suggests a potential causal association of the m6A‐related protein HNRNPC in the cause of IHD and verified the accuracy of the results through a series of experiments, which will help us understand the pathogenesis of IHD and identify potential therapeutic targets in the future.